Lexaria Bioscience Corp. LXRP Archives - Page 12 of 27

ThursdayJan 31, 2019 3:08 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Seeks to Improve Lives through Revolutionary Nicotine Delivery Method

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently announced that its wholly owned subsidiary, Lexaria Nicotine LLC, has joined forces with one of the world’s largest tobacco companies to fund the research and development of Lexaria’s patented DehydraTECHÔ technology to potentially commercialize a form of oral nicotine delivery. An article discussing the company reads, “Lexaria’s goal is to create an oral product that eliminates the need for inhalation and helps curb the smoking habits of consumers. Over 6 million deaths a year worldwide are attributed to nicotine delivery through smoking. The company believes that its DehydraTECH technology may help the 69…

ThursdayJan 31, 2019 10:22 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Receives New R&D Funding for Oral Nicotine Delivery Technology

LXRP subsidiary Lexaria Nicotine LLC enters definitive investment agreement with large tobacco company to receive R&D funding in exchange for licensing and equity Partner has provided initial $1 million – with an option for up to $11 million more – for research on DehydraTECH’s oral forms of nicotine delivery through a series of private financings LXRP still retains majority equity ownership of Lexaria Nicotine, while partner receives a minority equity interest in the subsidiary, not in LXRP itself Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH absorption platform will receive a significant injection of R&D financing under an investment agreement…

FridayJan 25, 2019 4:08 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Patented Drug Delivery Platform Could Revolutionize Nicotine Delivery

Biotechnology company and drug delivery platform innovator Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) technology is patent protected for cannabidiol and all other nonpsychoactive cannabinoids. The company also currently has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. An article discussing the company reads, “Lexaria Bioscience has 10 patents granted with over 50 patents pending. Four of the granted patents focus on the delivery of nicotine. The company is not partnering with the tobacco industry. However, Bunka informed that Lexaria is exploring the potential use of its DehydraTECH technology to help people stop smoking.…

ThursdayJan 24, 2019 11:35 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Acquires a $12 Million Investor

Lexaria Nicotine LLC partners with one of the world’s largest tobacco companies Opportunity to change nicotine delivery and improve the lives of millions Retains ownership of DehydraTECH while licensing the technology out to multiple industries Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) recently announced that its wholly owned subsidiary, Lexaria Nicotine LLC, has partnered with one of the world’s largest tobacco companies to fund the research and development of Lexaria’s patented DehydraTECH (http://ibn.fm/YwFuE). The partnership may potentially commercialize this cutting-edge technology for oral nicotine delivery. Chris Bunka, CEO of Lexaria Bioscience, is excited about the opportunity to work with a world-class…

ThursdayJan 17, 2019 11:26 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives $1 Million from New Partnership with Altria to Fund DehydraTECH R&D

LXRP’s subsidiary, Lexaria Nicotine LLC, enters definitive investment agreement with Altria Ventures Inc.; Altria to fund R&D, receive license rights and equity Altria will fund research on LXRP’s DehydraTECH oral nicotine products, pay sales royalties and may fund up to $12 million more through a series of private financings LXRP has not sold or optioned its own equity and still retains majority equity ownership of Lexaria Nicotine, LLC; Altria would receive minority equity interest in the subsidiary Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) wholly owned subsidiary, Lexaria Nicotine LLC, has entered a definitive investment agreement with Altria Group Inc.’s…

ThursdayJan 17, 2019 11:02 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Secures Up to $12M Altria Group Investment in DehydraTECH Technology

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that its wholly owned subsidiary, Lexaria Nicotine LLC, has entered into a definitive agreement with Altria Group Inc. (NYSE: MO) to fund the research and development of Lexaria’s patented DehydraTECH technology. The company’s DehydraTECH enhances the performance of ingestible products’ beneficial compounds across four categories that include taste and smell, speed of action, bio-absorption and bioavailability. According to the update, the partnership will explore innovation in oral, reduced-risk nicotine products for consumers, as well as potentially commercialize DehydraTECH for oral nicotine delivery. “This is an…

TuesdayJan 15, 2019 12:54 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiary Enters Definitive Investment Agreement with Altria Ventures Inc.

Drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that its wholly-owned subsidiary Lexaria Nicotine LLC has executed a definitive agreement with Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc. (NYSE: MO), to pursue innovation in oral, reduced risk nicotine consumer products using Lexaria's patented DehydraTECH™ technology. In exchange for a minority equity interest in Lexaria Nicotine and DehydraTECH™ license rights for oral nicotine delivery forms on an exclusive basis in the US and a non-exclusive basis elsewhere globally, Altria will fund a milestone-based research & development ("R&D") program to be executed by…

FridayJan 11, 2019 11:08 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Discusses Company Initiatives at O’Cannabiz 2018

Lexaria Bioscience has its innovative DehydraTECH drug delivery platform The company’s DehydraTECH technology is complementary to other R&D being done on cannabinoids Lexaria recently attended O’Cannabiz 2018 in Vancouver A biotech company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) offers a unique platform that makes it possible to deliver bioactive substances through oral ingestion. Its DehydraTECH technology accomplishes this without the need for unhealthy inhalational dosing. DehydraTECH uses only GRAS (Generally Recognized as Safe) ingredients and increases bio-absorption by five to 10 times. Based in Kelowna, British Columbia, Lexaria Bioscience is the only company globally with patents issued for the…

TuesdayJan 08, 2019 2:35 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Proprietary Technology Transforms the Way Molecules Enter the Body

Biotechnology company Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) revolutionary technology, DehydraTECH, alters the way that fat soluble, plant-derived molecules are absorbed into the body. A recent article further discussing the company reads, “Chemicals or intimidating complex ingredients that require disclosure on food labels are not required additions when using DehydraTECH. Instead the edible tech works with commons GRAS ingredients that can be organic and gluten- and dairy-free. It does all of this while still costing partners less than a penny per serving to implement, making DehydraTECH a win-win for the partner and consumer, who both gain from the improved performance…

FridayJan 04, 2019 12:28 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Brings Aggressive Growth Plan to Action

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently put its aggressive growth strategy into effect with the additions of a new corporate controller, a head of its legal division and more office staff. The company also intends to increase its lab personnel in 2019. A recent article further discussing the company reads, “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, has announced aggressive growth plans, including the addition of key personnel, a special focus on its lab R&D activities in 2019 and the issue of new stock options. … It…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP